PMID- 22441545
OWN - NLM
STAT- MEDLINE
DCOM- 20120801
LR  - 20220408
IS  - 1531-5487 (Electronic)
IS  - 1044-3983 (Linking)
VI  - 23
IP  - 3
DP  - 2012 May
TI  - Probiotics supplementation during pregnancy or infancy for the prevention of 
      atopic dermatitis: a meta-analysis.
PG  - 402-14
LID - 10.1097/EDE.0b013e31824d5da2 [doi]
AB  - BACKGROUND: The study of probiotics to prevent allergic conditions has yielded 
      conflicting results in children. We undertook a meta-analysis of randomized 
      controlled trials to investigate whether probiotic use during pregnancy and early 
      life decreases the incidence of atopic dermatitis and immunoglobulin E 
      (IgE)-associated atopic dermatitis in infants and young children. METHODS: We 
      performed a systematic literature search in Medline, Embase, and Cochrane 
      Library, updated to October 2011. The intervention was diet supplementation with 
      probiotics versus placebo. Primary outcomes were incidence of atopic dermatitis 
      and IgE-associated atopic dermatitis. We calculated summary relative risks (RRs) 
      and corresponding 95% confidence intervals (CIs), using both fixed- and 
      random-effects models. We computed summary estimates across several strata, 
      including study period, type of patient, dose, and duration of intervention, and 
      we assessed the risk of bias within and across trials. RESULTS: We identified 18 
      publications based on 14 studies. Meta-analysis demonstrated that probiotic use 
      decreased the incidence of atopic dermatitis (RR = 0.79 [95% CI = 0.71-0.88]). 
      Studies were fairly homogeneous (I = 24.0%). The corresponding RR of 
      IgE-associated atopic dermatitis was 0.80 (95% CI = 0.66-0.96). No appreciable 
      difference emerged across strata, nor was there evidence of publication bias. 
      CONCLUSIONS: This meta-analysis provided evidence in support of a moderate role 
      of probiotics in the prevention of atopic dermatitis and IgE-associated atopic 
      dermatitis in infants. The favorable effect was similar regardless of the time of 
      probiotic use (pregnancy or early life) or the subject(s) receiving probiotics 
      (mother, child, or both).
FAU - Pelucchi, Claudio
AU  - Pelucchi C
AD  - Mario Negri Institute for Pharmacological Research, Milan, Italy. 
      claudio.pelucchi@marionegri.it
FAU - Chatenoud, Liliane
AU  - Chatenoud L
FAU - Turati, Federica
AU  - Turati F
FAU - Galeone, Carlotta
AU  - Galeone C
FAU - Moja, Lorenzo
AU  - Moja L
FAU - Bach, Jean-Francois
AU  - Bach JF
FAU - La Vecchia, Carlo
AU  - La Vecchia C
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Epidemiology
JT  - Epidemiology (Cambridge, Mass.)
JID - 9009644
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Dermatitis, Atopic/immunology/*prevention & control
MH  - Female
MH  - Humans
MH  - Hygiene Hypothesis
MH  - Immunoglobulin E/immunology
MH  - Infant
MH  - Infant, Newborn
MH  - Models, Statistical
MH  - Pregnancy
MH  - Prenatal Care
MH  - Probiotics/*therapeutic use
MH  - Treatment Outcome
EDAT- 2012/03/24 06:00
MHDA- 2012/08/02 06:00
CRDT- 2012/03/24 06:00
PHST- 2012/03/24 06:00 [entrez]
PHST- 2012/03/24 06:00 [pubmed]
PHST- 2012/08/02 06:00 [medline]
AID - 10.1097/EDE.0b013e31824d5da2 [doi]
PST - ppublish
SO  - Epidemiology. 2012 May;23(3):402-14. doi: 10.1097/EDE.0b013e31824d5da2.